Nektar Therapeutics Aktie News

SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London. Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m.

SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.

SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025...

Nektar Therapeutics (NKTR -2.34%) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January.

Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusiastic about recently announced clinical trial results for its lead candidate, rezpegaldesleukin.

Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.

Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances, investors flocked to the stock, and it closed the trading session a bit more than 15% higher.